THE preliminary results of infectious complications in orthotopic liver transplantation IOLT) using FK 506 as a primary immunosuppressive agent were encouraging. I This early experience. however. was limited to only 20 patients who were followed for a short period of time. We have now extended our observations to 110 consecutive adult liver transplant recipients of first livers enrolled in the ...

Epidemiology and Transmission 487 Staphylococcus aureus 487 Coagulase-Negative Staphylococci 488 Microbiology 489 Staphylococcus aureus 489 Coagulase-Negative Staphylococci 490 Pathogenesis of Disease 490 Virulence Factors of Staphylococcus aureus 490 Epithelial Attachment and Invasion 490 Innate Immune Resistance 491 Secreted Toxins 492 Quorum Sensing and Regulation of Virulence Factor Express...

Severe graft-versus-host disease was induced by transplantation of ACI rat bone marrow and spleen cells into irradiated Lewis rat recipients. Treatment with FK 506 or cyclosporine A (CsA) was started after clinical and histologic evidence of acute GVHD was present. A 14-day course of FK 506 at 1.0 mg/kg/day could rescue 100% of the animals suffering from GVHD. In contrast only one half of the a...

The effect of a 14-day administration of FK-506 at 1 or 3 mgflcg ofi plasma lipids and myocardial energy and glucose metabolism in rats was investigated. FK-506 increased the level of blood glucose in rats when given daily at an oral dosage of 3 mgrkg for 14 days. T?ie plasma ]evel of total cholesterol was significantly increased by F}(-506 at either 1 or 3 mgXkg, whereas that of triglyceride w...

FK 506, a novel immunosuppressive agent, was first used to reverse rejection in liver recipients who had failed to respond to conventional therapy.' The successful outcome of the initial study has led to clinical trials of FK 506 as the primary immunosuppressive agent for liver allografts and other organ transplants. 2-4 Ongoing studies include dosage protocols for optimal immunosuppression wit...

Objective(s): To explore the correlation between expression patterns and functions of miR-383 and LDHA in hepatocellular cancer (HCC). Materials and Methods: We detected the expression of miR-383 and LDHA in 30 HCC tissues and their matched adjacent normal tissues using qRT-PCR. Then we performed MTT assay, foci formation assay, transwell migration assay, glucose uptake assay and lactate produc...